<DOC>
	<DOC>NCT02842983</DOC>
	<brief_summary>After initial hemodynamic stabilization, 36 septic shock patients with heart rate &gt; of 90 bpm and requiring norepinephrine to maintain mean arterial pressure (MAP) more than 65 mmHg will be randomised into two groups, esmolol group and control group. Patients allocated to esmolol group will receive a continuous esmolol infusion to maintain a lowering of heart rate of 10%. Norepinephrine will be titrated to achieve a MAP more than 65 mmHg. To investigate myocardial performance, the investigators will assess Tissue Doppler imaging by echocardiography and hemodynamic measures. Data will be obtained at baseline ,after esmolol infusion once achieved the predefined heart rate threshold and 72hours after esmolol infusion.</brief_summary>
	<brief_title>Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients</brief_title>
	<detailed_description>primary outcome were determined according to our previous study of tissue doppler.</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
	<criteria>septic shock fluid optimization with a cardiac index &gt; 3 l/min/m2 Heart Rate &gt;90 /min Cardiogenic shock Bradycardia History of Severe Asthma Indications against Esmolol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Esmolol</keyword>
	<keyword>Hypotension</keyword>
	<keyword>Shock, Septic</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
	<keyword>Adrenergic beta-1 Receptor Antagonists</keyword>
	<keyword>Adrenergic Antagonists</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>